NDC product
Nerlynx
NDC 70437-240 · Puma Biotechnology, Inc.
Key facts
| Product NDC | 70437-240 |
|---|---|
| Proprietary name | Nerlynx |
| Nonproprietary name | neratinib |
| Substances | NERATINIB MALEATE ANHYDROUS |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Puma Biotechnology, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA208051 |
| Pharmacologic classes | Kinase Inhibitor [EPC], Kinase Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA] |
| Marketing start | Jul 17, 2017 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: